About the founder

Eric Lloyd, MSci Pharmacology student at King's College London.
Why I built AssetMemo
I'm working towards a career in biotech investing. The tools I came across mostly gave a drug's odds of approval without showing how they got there, whereas I wanted something with science at the centre.
That's why I've been building AssetMemo. It looks at the trials behind each drug and grades how strong the evidence is, based on the trial design (number of patients enrolled, blinding, endpoints). You can read the full methodology here.
About me
I'm an MSci Pharmacology student at King's College London, graduating in 2028. I've worked in drug metabolism and pharmacokinetics (DMPK) at a contract research organisation, and I'm currently working on a research project defining CD8+ MAIT cells as a new predictive biomarker of response to biologics that target the IL-23/IL-17 axis in psoriasis.
I built AssetMemo's data pipeline, grading rubric and website myself.
Get in touch
For roles, opportunities, or feedback on the site: LinkedIn or eric@assetmemo.bio. For data corrections, support@assetmemo.bio.